Cargando…

Clinical efficacy of emollients in atopic dermatitis patients – relationship with the skin microbiota modification

BACKGROUND: We speculated that an emollient supplemented with a biomass of nonpathogenic bacteria such as Vitreoscilla filiformis (Vf), grown in a medium containing thermal spring water (LRP-TSW); (LRP-Vitreoscilla filiformis biomass [LRP-VFB]), could have a beneficial effect for patients with atopi...

Descripción completa

Detalles Bibliográficos
Autores principales: Seité, Sophie, Zelenkova, Hana, Martin, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5238811/
https://www.ncbi.nlm.nih.gov/pubmed/28138262
http://dx.doi.org/10.2147/CCID.S121910
_version_ 1782495779899834368
author Seité, Sophie
Zelenkova, Hana
Martin, Richard
author_facet Seité, Sophie
Zelenkova, Hana
Martin, Richard
author_sort Seité, Sophie
collection PubMed
description BACKGROUND: We speculated that an emollient supplemented with a biomass of nonpathogenic bacteria such as Vitreoscilla filiformis (Vf), grown in a medium containing thermal spring water (LRP-TSW); (LRP-Vitreoscilla filiformis biomass [LRP-VFB]), could have a beneficial effect for patients with atopic dermatitis (AD). PATIENTS AND METHODS: This double-blind, randomized, comparative study was conducted with 60 patients with moderate AD. Before starting the study, participants were pretreated for 15 days with drug therapy to improve their SCORing Atopic Dermatitis (SCORAD) by at least 25%. On Day 1, the eligible patients were randomized to either the emollient containing LRP-VFB associated with mannose (Product A) or another emollient (product B) and were treated twice daily for 1 month. Recurrence of flare-ups and microbial communities were characterized from swabs taken at Day 1 and Day 28, under axenic conditions, from affected (AF) and proximal unaffected (UAF) skin areas. RESULTS: At Day 1, the average SCORAD of each group and the microbial communities of AF and UAF areas for each participant were similar. One month after the end of the therapeutic treatment (Day 28), the average evolution of SCORAD at Day 28 compared to Day 1 of patients treated with product A was significantly lower than that of the patients treated with product B. A significantly increased level of Xanthomonas genus was noticed in the group treated with product A (versus product B). On the other hand, the level of Staphylococcus genus increased between Day 1 and Day 28 in the group treated with product B, but not in the group treated with product A. Interestingly, these differences were more pronounced for patients in relapse, and the associated SCORAD worsening was less in the group treated with product A versus the group treated with product B. CONCLUSION: This study demonstrated that a specific emollient containing a biomass of non-pathogenic bacteria Vf grown in a medium containing TSW and associated with a selected carbon source is able to normalize skin microbiota and significantly reduce the number and severity of flare-ups compared with another emollient.
format Online
Article
Text
id pubmed-5238811
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-52388112017-01-30 Clinical efficacy of emollients in atopic dermatitis patients – relationship with the skin microbiota modification Seité, Sophie Zelenkova, Hana Martin, Richard Clin Cosmet Investig Dermatol Original Research BACKGROUND: We speculated that an emollient supplemented with a biomass of nonpathogenic bacteria such as Vitreoscilla filiformis (Vf), grown in a medium containing thermal spring water (LRP-TSW); (LRP-Vitreoscilla filiformis biomass [LRP-VFB]), could have a beneficial effect for patients with atopic dermatitis (AD). PATIENTS AND METHODS: This double-blind, randomized, comparative study was conducted with 60 patients with moderate AD. Before starting the study, participants were pretreated for 15 days with drug therapy to improve their SCORing Atopic Dermatitis (SCORAD) by at least 25%. On Day 1, the eligible patients were randomized to either the emollient containing LRP-VFB associated with mannose (Product A) or another emollient (product B) and were treated twice daily for 1 month. Recurrence of flare-ups and microbial communities were characterized from swabs taken at Day 1 and Day 28, under axenic conditions, from affected (AF) and proximal unaffected (UAF) skin areas. RESULTS: At Day 1, the average SCORAD of each group and the microbial communities of AF and UAF areas for each participant were similar. One month after the end of the therapeutic treatment (Day 28), the average evolution of SCORAD at Day 28 compared to Day 1 of patients treated with product A was significantly lower than that of the patients treated with product B. A significantly increased level of Xanthomonas genus was noticed in the group treated with product A (versus product B). On the other hand, the level of Staphylococcus genus increased between Day 1 and Day 28 in the group treated with product B, but not in the group treated with product A. Interestingly, these differences were more pronounced for patients in relapse, and the associated SCORAD worsening was less in the group treated with product A versus the group treated with product B. CONCLUSION: This study demonstrated that a specific emollient containing a biomass of non-pathogenic bacteria Vf grown in a medium containing TSW and associated with a selected carbon source is able to normalize skin microbiota and significantly reduce the number and severity of flare-ups compared with another emollient. Dove Medical Press 2017-01-12 /pmc/articles/PMC5238811/ /pubmed/28138262 http://dx.doi.org/10.2147/CCID.S121910 Text en © 2017 Seité et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Seité, Sophie
Zelenkova, Hana
Martin, Richard
Clinical efficacy of emollients in atopic dermatitis patients – relationship with the skin microbiota modification
title Clinical efficacy of emollients in atopic dermatitis patients – relationship with the skin microbiota modification
title_full Clinical efficacy of emollients in atopic dermatitis patients – relationship with the skin microbiota modification
title_fullStr Clinical efficacy of emollients in atopic dermatitis patients – relationship with the skin microbiota modification
title_full_unstemmed Clinical efficacy of emollients in atopic dermatitis patients – relationship with the skin microbiota modification
title_short Clinical efficacy of emollients in atopic dermatitis patients – relationship with the skin microbiota modification
title_sort clinical efficacy of emollients in atopic dermatitis patients – relationship with the skin microbiota modification
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5238811/
https://www.ncbi.nlm.nih.gov/pubmed/28138262
http://dx.doi.org/10.2147/CCID.S121910
work_keys_str_mv AT seitesophie clinicalefficacyofemollientsinatopicdermatitispatientsrelationshipwiththeskinmicrobiotamodification
AT zelenkovahana clinicalefficacyofemollientsinatopicdermatitispatientsrelationshipwiththeskinmicrobiotamodification
AT martinrichard clinicalefficacyofemollientsinatopicdermatitispatientsrelationshipwiththeskinmicrobiotamodification